Combination of Ibrutinib and As2O3 in the Treatment of CLL

• Status: Unknown status
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether the combination of As2O3 and ibrutinib is synergistic in chronic lymphocytic leukemia

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Peking University People's Hospital
• Collaborator: Beijing Hospital
• Treatments: Arsenic Trioxide

Criteria

Inclusion Criteria:

• patients fulfilling clinical and immune-phenotypic criteria for CLL

Exclusion Criteria:

• none